167933-07-5

Basic information

• Product Name: Flibanserin
• Synonyms: Flibanserin,Bimt 17, Bimt-17-BS,Girosa;2H-Benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-;Flibanserin;Bimt 17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one;Filbanserin;Flibanerins;1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one
• CAS NO: 167933-07-5
• Molecular Formula: C20H21F3N4O
• Molecular Weight: 390.4
• EINECS: 1806241-263-5
• Product Categories: API,chemical material;API;Flibanserin ada@tuskwei.com sky;18031153937@189.cn
• Mol File: 167933-07-5.mol
• Article Data: 15

Chemical Properties

• Appearance: white to beige/
• Density: 1.292 g/cm³
• Refractive Index: 1.566
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble10mg/mL, clear
• PKA: 12.12±0.30(Predicted)
• CAS DataBase Reference: Flibanserin(CAS DataBase Reference)
• NIST Chemistry Reference: Flibanserin(167933-07-5)
• EPA Substance Registry System: Flibanserin(167933-07-5)

Safety Data

• Hazard Codes: T
• Statements: 25-36/37/38
• Safety Statements: 26-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 167933-07-5(Hazardous Substances Data)

Usage

Description

Flibanserin is a first-in-class oral medication, originally developed by Boehringer-Ingelheim and later by Sprout Pharmaceuticals, which was approved by the FDA in 2015 for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). It is a multifunctional serotonin agonist and antagonist, acting as a full agonist of the 5-HT1A receptor, an antagonist of the 5-HT2A receptor, and a partial agonist of the dopamine-4 (D4) receptor. This unique mechanism of action leads to increased dopamine and norepinephrine levels, along with decreased serotonin levels, making it a promising pharmaceutical candidate for addressing women's sexual function.

Uses

Used in Pharmaceutical Industry:
Flibanserin is used as a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD) to increase sexual desire, not performance. It is the first prescription medicine for the treatment of this sexual dysfunction.
Used as a Serotonergic Agonist and Antagonist:
Flibanserin is used as a serotonergic agonist and antagonist for its role in modulating serotonin levels, which contributes to its effectiveness in treating HSDD.
Used as an Antidepressant:
Flibanserin is used as an antidepressant, leveraging its 5-HT1A agonist and 5-HT2 antagonist properties to help alleviate symptoms of depression.

Mechanism of action

Flibanserin is a novel multifunctional serotonin agonist and antagonist (MSAA) that improves sexual functioning in premenopausal women who suffer from reduced sexual interest and desire.Flibanserin theoretically improves sexual functioning by enhancing downstream release of dopamine and norepinephrine while reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire. Flibanserin has demonstrated clinical efficacy in premenopausal women who have reduced interest in and desire for sex and has 2 principal pharmacologic actions in microcircuits: it is a full agonist at postsynaptic serotonin 5HT1A receptors and an antagonist at postsynaptic 5HT2A receptors..Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors.

Drugs for enhancing female sexuality

Flibanserin is the world's first New drug for enhancing female sexuality. It can reduce the amount of 5-hydroxytryptamine which inhibits sexuality and improve sexual stimulant dopamine levels. It is already submitted to Food and Drug Administration of the United States for approval. This drug can directly effect on the? sexual pleasure control area of the female brain to restore female Flagging libido. By adjusting the aphrodisiac body system, Flibanserin Helps to restore the balance of sexual appetite suppression and exciting mechanism and lead to form a healthy sexual performance. The curative effect can be obtained a few weeks later. At the same time, the female viagra also has a certain side effects. One-eighth of tested women appeared dizziness, fatigue and sleepiness. Similar to antidepressants, Flibanserin will affect the brain secretion chemicals associated with emotions and desires. In fact, it was used as a drug for the treatment of depression before before it becomes a sex medicine. Different from the working principle of "viagra", Flibanserin works by adjusting the chemicals in female brains. In addition, "viagra" only works for most men, Flibanserin has effects on women with low libido. If the patient does not have a sexual interest to someone, Flibanserin will not affect her. Flibanserin will not cause hyperaphrodisia. Clayton. Anita, adviser of the drug companies says :“it is not an aphrodisiac and it only helps to balance the chemicals in the female brain to make a female restore sex desire, but not more than the normal level. However, it takes some time for this drug to work and women should take the drug every day. Figure 1 shows Flibanserin tablet.

Biochem/physiol Actions

Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist. Flibanserin has high affinity for human 5-HT1A receptors (Ki = 1 nm) and lower affinity for 5-HT2A (Ki = 49 nm) and D4 (Ki = 4–24 nm) receptors, and negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin. Recently, Flibanserin was found to reduce L-DOPA-induced dyskinesia in a model of Parkinson′s Disease.

Synthesis

The large-scale synthesis of flibanserin (X) mostly follows a patent from Symed Laboratories Limited which demonstrated hundred-gram-scale preparation of the drug as described in Scheme. Starting from commercially available 1-(prop-1- en-2-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (74), installation of an ethylene side chain was accomplished under conventional alkylation conditions with 1,2-dibromoethane and base, and this event was immediately followed by a second alkylation reaction involving piperazine to secure piperazinyl benzimidazolone 75. Interestingly, the enamine double bond within 74 was apparently reduced to the corresponding isopropyl group under these conditions. Although the authors do not comment about this reduction directly, similar examples of olefin reduction under non-hydrogenative alkylation conditions have been reported in the literature separately by both Pai and Ryu. Removal of the isopropyl group was facilitated by means of aqueous sodium hydroxide to afford 76, which underwent N-arylation under Buchwald conditions with 1-bromo-3-(trifluoromethyl)benzene 77 to furnish flibanserin (X) in 63% yield.

in vitro

previous study found that flibanserin was a 5-ht(1a) agonist, a very weak partial agonist on dopamine d(4) receptors, and a 5-ht(2a) antagonist. flibanserin could reduce neuronal firing rate and flibanserin-induced reduction in firing rate was likely mediated via stimulation of postsynaptic 5-ht(1a) receptors. moreover, flibanserin could quickly desensitize somatic 5-ht autoreceptors and enhance tonic activation of postsynaptic 5-ht(1a) receptors. in addition, flibanserin was able to reduce synthesis and extracellular levels of 5-ht in the cortex [1].

in vivo

previous animal study showd that flibanserin had antidepressant-like activity in most animal models sensitive to antidepressants, and such activity seemed different from that exerted by other antidepressants. in addition, flibanserin did not show consistent effects in animal models of anxiety and seemed to exert potential antipsychotic effects [1].

references

[1] borsini f, evans k, jason k, rohde f, alexander b, pollentier s. pharmacology of flibanserin. cns drug rev. 2002 summer;8(2):117-42.[2] katz m et al. efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the begonia trial. j sex med. 2013 jul;10(7):1807-15.

InChI:InChI=1/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)

Upstream product

• 401-78-5 3-bromo-1-trifluoromethylbenzene 
• 1971858-36-2 1-(prop-1-en-2-yl)-3-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one 
• 95-54-5 1,2-diamino-benzene 
• 52099-72-6 1,3-dihydro-1-(1-methylethenyl)-2H-benzimidazol-2-one 
• 147359-76-0 BIMT 17 hydrochloride 
• 136081-17-9 1-(2-bromoethyl)-3-(prop-1-en-2-yl)-1H-benzo[d]imidazol-2(3H)-one 
• 22219-23-4 2-ethoxy-1H-benzo[d]imidazole 
• 136702-12-0 1-(2-chloro-ethyl)-3-isopropenyl-1,3-dihydro-benzoimidazol-2-one 
• 57061-71-9 1-chloro-2-[4-(3-trifluoromethylphenyl)piperazin-1-yl]ethane 
• 530-62-1 1,1'-carbonyldiimidazole 
• 98-16-8 3-trifluoromethylaniline 
• 36647-05-9 tris(2-bromoethyl)amine 
• 28643-53-0 1,3-dihydro-1-(phenylmethyl)-2H-benzimidazol-2-one 
• 81942-81-6 1-(2-Hydroxy-ethyl)-3-isopropenyl-1,3-dihydro-benzoimidazol-2-one 

Relevant articles and documents

Synthetic method of flibaserin

The invention relates to a synthesis method of flibaserin, and belongs to the technical field of organic synthesis. The method comprises the following steps: by taking methyl anthranilate as an initial raw material, firstly carrying out amido alkylation reaction on the methyl anthranilate and 1-(2-chloroethyl)-4-[3-(trifluoromethyl) phenyl] piperazine dihydrochloride under the action of alkali, then, carrying out alkaline hydrolysis to remove methyl ester, and finally, carrying out schmidt reaction under the action of diphenylphosphoryl azide to obtain the flibaserin. The method is novel in route design, short in synthesis step and few in by-products; and the method has the advantages of simple operation, simple post-treatment process, low requirements on reaction equipment, cheap and easily available raw materials, economy, environmental protection and suitableness for industrial production.

A new method for synthesizing flibanserin (by machine translation)

The invention relates to a new method for synthesizing of flibanserin, which belongs to the technical field of organic synthesis. The invention respectively in order to triethanolamine and between amino benzotrifluoride as the starting material, to prepare the piperazine intermediate; then to the O-phenylene diamine and the original four carbonate as raw material, the preparation of the ethoxy and imidazole intermediate; the obtained piperazine intermediate and benzimidazole intermediate undergo the substitution reaction, and hydrochloric acid deprotection to obtain the target product of flibanserin. The invention has few synthetic steps, few by-products, intermediate products and the target product yield is relatively high, intermediate product 2 - ethoxy and imidazole yield up 94.2%, the target product yield can reach 56.2%, it can be seen, the invention overcomes the substance in the prior art synthesis step is tedious, and more byproducts, target low yield of product defect. In addition, the present invention has a simple structure, high purity of product, the economic and environmental protection industrial line, has a very wide range of use and potential economic benefits. (by machine translation)

N-Arylation of DABCO with Diaryliodonium Salts: General Synthesis of N-Aryl-DABCO Salts as Precursors for 1,4-Disubstituted Piperazines

Employing DABCO as a substrate, aryl(mesityl)iodonium triflates are introduced as arylating agents for a tertiary sp3-nitrogen. Mild conditions and exceptional selectivity of the aryl group transfer allow unprecedented N-aryl-DABCO salts to be obtained, bearing substituents of different electronic natures. This metal-free methodology has no analogy among known transition-metal-based reactions. The utility of isolated N-aryl-DABCO salts is demonstrated for the preparation of flibanserin.